Company Will Bring Personalized Medicine to Behavioral Healthcare
CINCINNATI, September 17, 2008 – AssureRx Health Inc., a personalized medicine company, announced today that it has entered into a strategic relationship with Diamond Healthcare Corporation of Richmond, VA, the nation’s largest privately-held behavioral health and management consulting firm. AssureRx’s personalized medicine platform, based on technology from the Mayo Clinic and Cincinnati Children’s Hospital, helps physicians determine the right drug and right dose for patients suffering from Behavioral Health conditions. The relationship will provide AssureRx with access to Diamond’s extensive managerial and clinical expertise and industry relationships and accelerate AssureRx’s commercial introduction of its first personalized medicine product for the Behavioral Health marketplace.
“At Diamond, we have built our reputation by demonstrating a commitment to providing the highest level of quality service to our patients. In this rapidly changing healthcare environment, we are working even harder to bring high-quality, innovative solutions that can improve clinical and financial outcomes to our hospitals and health systems. Our strategic partnership with AssureRx is completely aligned with these objectives,” said George K. White, President and CEO of Diamond.
“Diamond is an ideal partner for our technology. The company’s depth of expertise and deep understanding of the behavioral health marketplace will help us deliver solutions that are meaningful to patients and economically beneficial to payers and providers,” said Mark Byrne, CEO of AssureRx. “We are also pleased to welcome George White, Diamond’s CEO, as a key addition to our Board.”
About GeneSight
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.